Our offering

Explore the Kite Cell Therapy Hub for tailored, on-demand videos and resources to further your knowledge, understanding of the data relating to CAR T and practical skills throughout the CAR T-cell journey: from the identification of appropriate patients who may benefit from CAR T-cell therapy and timely referral, to patient communication and optimisation, as well as post CAR T management and follow-up.

LEARN FROM EXPERT PERSPECTIVES

Featuring Dr Miguel-Angel Perales

Dr Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, USA, reviews ZUMA-7's overall survival outcomes with axicabtagene cilolucel in the treatment of R/R DLBCL and its potential implications for bridging strategies

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

WATCH OUR LATEST CONGRESS PRESENTATIONS

Featuring Prof. Marie José Kersten

Prof. Marie José Kersten introduces the symposium which focuses on improving outcomes in relapsed refractory DLBCL

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.